Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

The Quietude Study: Quetiapine Use for Agitated Depression

First Posted Date
2011-06-01
Last Posted Date
2014-01-08
Lead Sponsor
Physicians Research And Education Network
Target Recruit Count
250
Registration Number
NCT01363310
Locations
🇨🇦

Manna Research, Toronto, Ontario, Canada

🇨🇦

Georgina Family Medical Centre, Keswick, Ontario, Canada

🇨🇦

Aggarwal and Associates Ltd, Brampton, Ontario, Canada

and more 8 locations

Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder

First Posted Date
2011-03-07
Last Posted Date
2013-01-25
Lead Sponsor
Samsung Medical Center
Target Recruit Count
164
Registration Number
NCT01309776
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

🇰🇷

Inje University Paik Hospital, Goyang, Korea, Republic of

and more 3 locations

The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients

Phase 4
Conditions
Interventions
First Posted Date
2011-01-19
Last Posted Date
2014-10-09
Lead Sponsor
Asan Medical Center
Target Recruit Count
444
Registration Number
NCT01278498
Locations
🇰🇷

Kangwon National University Hospital, Chuncheon, Gangwon, Korea, Republic of

🇰🇷

Kwandong University College of Medicine Myongji Hospital, Gyeonggi-do, Goyang, Korea, Republic of

🇰🇷

Dong-A University Hospital, Busan, Korea, Republic of

and more 13 locations

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-01-06
Last Posted Date
2019-05-07
Lead Sponsor
VA Nebraska Western Iowa Health Care System
Target Recruit Count
26
Registration Number
NCT01271244
Locations
🇺🇸

Omaha Veterans Affairs Medical Center, Omaha, Nebraska, United States

Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-12-02
Last Posted Date
2016-10-31
Lead Sponsor
Medical University of Vienna
Target Recruit Count
26
Registration Number
NCT01251471
Locations
🇦🇹

Medical University of Vienna, Dept. of Psychiatry and Psychotherapy, Vienna, Austria

Lexapro for Major Depression in Patients With Epilepsy

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2010-11-19
Last Posted Date
2018-07-11
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
26
Registration Number
NCT01244724
Locations
🇺🇸

Weill Medical College of Cornell University, New York, New York, United States

EScitalopram PIndolol ONset of Action

First Posted Date
2010-10-13
Last Posted Date
2015-05-27
Lead Sponsor
Markus KOSEL
Target Recruit Count
18
Registration Number
NCT01219686
Locations
🇨🇭

Centre de Thérapies Breves (CTB), Secteur Jonction, Geneva, Switzerland

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-09-10
Last Posted Date
2014-03-14
Lead Sponsor
Forest Laboratories
Target Recruit Count
162
Registration Number
NCT01198795
Locations
🇺🇸

Forest Investigative Site 017, Atlanta, Georgia, United States

🇺🇸

Forest Investigative Site 010, Dallas, Texas, United States

🇺🇸

Forest Investigative Site 013, Jacksonville Beach, Florida, United States

and more 13 locations

Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder

First Posted Date
2010-06-22
Last Posted Date
2016-11-08
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
294
Registration Number
NCT01148472
© Copyright 2024. All Rights Reserved by MedPath